Placebo + AZD0780
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Oct 30, 2024 → May 2, 2025
NCT ID
NCT06692764About Placebo + AZD0780
Placebo + AZD0780 is a phase 2 stage product being developed by AstraZeneca for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06692764. Target conditions include Atherosclerotic Cardiovascular Disease.
What happened to similar drugs?
8 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06692764 | Phase 2 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease